-
公开(公告)号:US09228017B2
公开(公告)日:2016-01-05
申请号:US13257112
申请日:2010-03-19
IPC分类号: C07K16/28
CPC分类号: C07K16/2866 , C07K2317/52 , C07K2317/522 , C07K2317/526 , C07K2317/53 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要: By altering amino acid sequence, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated.
摘要翻译: 通过改变氨基酸序列,本发明人成功地提供了可赋予具有良好性质的抗体的恒定区域,特别是作为药物。 当应用于抗体生产时,由本发明提供的恒定区的变体将显着降低异质性。 也就是说,通过将本发明提供的改变引入抗体重链恒定区,可以将抗体的均一性保持在高水平。 更具体地,可以防止由抗体分子的重链中的-SS-键连接差引起的同质性的降低。 此外,在本发明的优选实施方案中,可以改善抗体的药代动力学,并且可以改善由抗体恒定区中的C末端缺失引起的同质性降低。
-
公开(公告)号:US09340615B2
公开(公告)日:2016-05-17
申请号:US13320317
申请日:2010-05-14
申请人: Atsuhiko Maeda , Hajime Miyamoto , Taichi Kuramochi , Atsushi Matsuo , Tomoyuki Igawa , Hirotake Shiraiwa , Hiroyuki Tsunoda , Tatsuhiko Tachibana
发明人: Atsuhiko Maeda , Hajime Miyamoto , Taichi Kuramochi , Atsushi Matsuo , Tomoyuki Igawa , Hirotake Shiraiwa , Hiroyuki Tsunoda , Tatsuhiko Tachibana
CPC分类号: C07K16/2863 , A61K2039/505 , C07K16/303 , C07K2317/24 , C07K2317/30 , C07K2317/76 , C07K2317/92
摘要: An objective of the present invention is to decrease the immunogenicity of mouse-derived anti-AXL antibodies in humans by humanizing them. The present invention provides antibodies that can bind to a specific region in Anexelekto (AXL) and humanized antibodies that are produced based on such antibodies. The anti-AXL antibodies of the present invention have high antitumor activity, and are useful as agents for decreasing the AXL expression level, antitumor agents, and diagnostic agents for cancer.
摘要翻译: 本发明的目的是通过人源化来降低小鼠来源的抗AXL抗体在人体中的免疫原性。 本发明提供可以结合Anexelekto(AXL)中的特定区域的抗体和基于此类抗体产生的人源化抗体。 本发明的抗AXL抗体具有高抗肿瘤活性,可用作降低AXL表达水平的药剂,抗肿瘤剂和癌症诊断剂。
-
公开(公告)号:US08562991B2
公开(公告)日:2013-10-22
申请号:US12680087
申请日:2009-09-25
申请人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
发明人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
IPC分类号: A61K39/395
CPC分类号: C07K16/2866 , A61K39/00 , A61K2039/505 , C07K16/461 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92
摘要: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
摘要翻译: 本发明通过改变作为人源化抗IL-6受体IgG1抗体的TOCILIZUMAB的可变区和恒定区的氨基酸序列来提供优于TOCILIZUMAB的第二代分子的药物组合物,以增强抗原 - 中和能力增强,药代动力学改善,治疗效果较差,免疫原性,安全性和物理化学性质(稳定性和均一性)均有改善。 本发明还提供了制备这些药物组合物的方法。 通过适当地组合CDR结构域,可变区和恒定区中的氨基酸序列改变,本发明人成功地生产出优于TOCILIZUMAB的第二代分子。
-
公开(公告)号:US20120253016A1
公开(公告)日:2012-10-04
申请号:US13524528
申请日:2012-06-15
申请人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
发明人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
CPC分类号: C07K16/2866 , A61K39/00 , A61K2039/505 , C07K16/461 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92
摘要: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
摘要翻译: 本发明通过改变作为人源化抗IL-6受体IgG1抗体的TOCILIZUMAB的可变区和恒定区的氨基酸序列来提供优于TOCILIZUMAB的第二代分子的药物组合物,以增强抗原 - 中和能力增强,药代动力学改善,治疗效果较差,免疫原性,安全性和物理化学性质(稳定性和均一性)均有改善。 本发明还提供了制备这些药物组合物的方法。 通过适当地组合CDR结构域,可变区和恒定区中的氨基酸序列改变,本发明人成功地生产出优于TOCILIZUMAB的第二代分子。
-
公开(公告)号:US20120071634A1
公开(公告)日:2012-03-22
申请号:US13257145
申请日:2010-03-19
IPC分类号: C07K16/18
CPC分类号: C07K16/00 , C07K16/2866 , C07K16/2875 , C07K2317/515 , C07K2317/52 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/528 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要: By altering amino acid sequences, the present inventors successfully produced constant regions that can confer antibodies with particularly favorable properties for pharmaceutical agents. When used to produce antibodies, the altered constant regions produced according to the present invention significantly reduce heterogeneity. Specifically, the antibody homogeneity can be achieved by using antibody heavy chain and light chain constant regions introduced with alterations provided by the present invention. More specifically, the alterations can prevent the loss of homogeneity of antibody molecules due to disulfide bond differences in the heavy chain. Furthermore, in a preferred embodiment, the present invention can improve antibody pharmacokinetics as well as prevent the loss of homogeneity due to C-terminal deletion in antibody constant region.
摘要翻译: 通过改变氨基酸序列,本发明人成功地制备了可赋予具有特别有利于药剂特性的抗体的恒定区域。 当用于产生抗体时,根据本发明产生的改变的恒定区域显着降低异质性。 具体而言,抗体均一性可以通过使用由本发明提供的改变引入的抗体重链和轻链恒定区来实现。 更具体地,改变可以防止由于重链中的二硫键差异导致的抗体分子的均匀性的丧失。 此外,在优选的实施方案中,本发明可以改善抗体药代动力学,并且可以防止由于抗体恒定区域中的C-末端缺失导致的均一性丧失。
-
公开(公告)号:US20120065379A1
公开(公告)日:2012-03-15
申请号:US13257112
申请日:2010-03-19
IPC分类号: C07K16/00
CPC分类号: C07K16/2866 , C07K2317/52 , C07K2317/522 , C07K2317/526 , C07K2317/53 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要: By means of amino acid sequence alterations, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production. That is, homogeneity of antibodies can be maintained at a high level by introducing the alterations provided by the present invention into the antibody heavy chain constant regions. More specifically, decrease in homogeneity caused by —SS— bond linkage differences in the heavy chains of antibody molecules can be prevented. Furthermore, in a preferred embodiment of the present invention, pharmacokinetics of antibodies can be improved and decrease in homogeneity caused by deletion of the C terminus in the antibody constant region can be ameliorated.
摘要翻译: 通过氨基酸序列改变,本发明人成功地提供了可赋予具有良好性质的抗体的恒定区域,特别是作为药物。 当应用于抗体生产时,由本发明提供的恒定区的变体将显着降低异质性。 也就是说,通过将本发明提供的改变引入抗体重链恒定区,可以将抗体的均一性保持在高水平。 更具体地,可以防止由抗体分子的重链中的-SS-键连接差引起的同质性的降低。 此外,在本发明的优选实施方案中,可以改善抗体的药代动力学,并且可以改善由抗体恒定区中的C末端缺失引起的同质性降低。
-
公开(公告)号:US20120121587A1
公开(公告)日:2012-05-17
申请号:US13320317
申请日:2010-05-14
申请人: Atsuhiko Maeda , Hajime Miyamoto , Taichi Kuramochi , Atsushi Matsuo , Tomoyuki Igawa , Hirotake Shiraiwa , Hiroyuki Tsunoda , Tatsuhiko Tachibana
发明人: Atsuhiko Maeda , Hajime Miyamoto , Taichi Kuramochi , Atsushi Matsuo , Tomoyuki Igawa , Hirotake Shiraiwa , Hiroyuki Tsunoda , Tatsuhiko Tachibana
IPC分类号: A61K39/395 , A61P35/00 , C07K16/28
CPC分类号: C07K16/2863 , A61K2039/505 , C07K16/303 , C07K2317/24 , C07K2317/30 , C07K2317/76 , C07K2317/92
摘要: An objective of the present invention is to decrease the immunogenicity of mouse-derived anti-AXL antibodies in humans by humanizing them. The present invention provides antibodies that can bind to a specific region in Anexelekto (AXL) and humanized antibodies that are produced based on such antibodies. The anti-AXL antibodies of the present invention have high antitumor activity, and are useful as agents for decreasing the AXL expression level, antitumor agents, and diagnostic agents for cancer.
摘要翻译: 本发明的目的是通过人源化来降低小鼠来源的抗AXL抗体在人体中的免疫原性。 本发明提供可以结合Anexelekto(AXL)中的特定区域的抗体和基于此类抗体产生的人源化抗体。 本发明的抗AXL抗体具有高抗肿瘤活性,可用作降低AXL表达水平的药剂,抗肿瘤剂和癌症诊断剂。
-
公开(公告)号:US20110245473A1
公开(公告)日:2011-10-06
申请号:US12680112
申请日:2008-09-26
申请人: Tomoyuki Igawa , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Atsuhiko Maeda
发明人: Tomoyuki Igawa , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Atsuhiko Maeda
IPC分类号: C07K16/28
CPC分类号: C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6854 , G01N33/6869 , G01N2333/7155 , G01N2500/04 , G01N2500/10
摘要: The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under acidic conditions, and stability in high concentration preparations.
摘要翻译: 本发明人成功地发现了TOCILIZUMAB的可变区,框架区和恒定区中的特异性氨基酸突变,这使得能够降低源自铰链区的二硫键的免疫原性风险和异质性,并且改善抗原结合 活性,药代动力学,酸性条件下的稳定性和高浓度制剂中的稳定性。
-
公开(公告)号:US20110098450A1
公开(公告)日:2011-04-28
申请号:US12680087
申请日:2009-09-25
申请人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
发明人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
CPC分类号: C07K16/2866 , A61K39/00 , A61K2039/505 , C07K16/461 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92
摘要: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
摘要翻译: 本发明通过改变作为人源化抗IL-6受体IgG1抗体的TOCILIZUMAB的可变区和恒定区的氨基酸序列来提供优于TOCILIZUMAB的第二代分子的药物组合物,以增强抗原 - 中和能力增强,药代动力学改善,治疗效果较差,免疫原性,安全性和物理化学性质(稳定性和均一性)均有改善。 本发明还提供了制备这些药物组合物的方法。 通过适当地组合CDR结构域,可变区和恒定区中的氨基酸序列改变,本发明人成功地生产出优于TOCILIZUMAB的第二代分子。
-
公开(公告)号:US09688762B2
公开(公告)日:2017-06-27
申请号:US12680082
申请日:2008-09-26
申请人: Tomoyuki Igawa , Hirotake Shiraiwa
发明人: Tomoyuki Igawa , Hirotake Shiraiwa
CPC分类号: C07K16/2866 , C07K16/00 , C07K2317/52 , C07K2317/53 , C07K2317/71
摘要: The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fcγ receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.
-
-
-
-
-
-
-
-
-